Active — Not RecruitingPhase 2

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

United States267 participantsStarted 2025-12-02

Plain-language summary

This Study is a Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participant's age at the time of signing the informed consent:
✓. BMI ≥30 kg/m² and ≤50 kg/m², or ≥27 kg/m² and \<30 kg/m² with ≥1 weight-related comorbidity
✓. Body weight change \<5% over the past 3 months prior to screening
✓. Capable of giving signed informed consent, ability and willingness to comply with all protocol procedures

Exclusion criteria

✕. Type 1 diabetes mellitus or T2DM, or HbA1c ≥6.5% / FPG ≥126 mg/dL
✕. Obesity due to endocrine/genetic disorders
✕. Planned or prior obesity surgery (unless \>1 year ago for liposuction/abdominoplasty), or device-based obesity therapy (unless removed \>6 months ago)
✕. Personal history or current diagnosis of acute or chronic pancreatitis or factors that may increase the risk of pancreatitis, such as a history of cholelithiasis (without cholecystectomy) or alcohol abuse.
✕. Personal or family history of medullary thyroid carcinoma (MTC) or a known genetic condition (e.g., multiple endocrine neoplasia type 2) that predisposes the participant to MTC.
✕. Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
✕. History or current diagnosis of congestive heart failure (NYHA class Ⅲ or Ⅳ), or myocardial infarction, stroke, unstable angina, transient ischemic attack, or revascularization procedure (e.g., stent or bypass graft surgery) within 3 months prior to screening visit
✕. Personal history or current diagnosis of acute or chronic pancreatitis or factors that may increase the risk of pancreatitis, such as a history of cholelithiasis (without cholecystectomy) or alcohol abuse.

What they're measuring

Percent Change in Body Weight.

Timeframe: Up to 41 weeks

Trial details

NCT IDNCT07205900

SponsorHanmi Pharmaceutical Company Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-01

View on ClinicalTrials.gov More Obese trials